

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10568572
Filing Date	2006-08-14
First Named Inventor	Heidi Lopez de Diego et al.
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	453-US-PCT

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568572
Filing Date	2006-08-14
First Named Inventor	Heidi Lopez de Diego et al.
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	453-US-PCT

/E.B./	1	Klaus P. Bøgesø, Drug Hunting: The Medicinal Chemistry of 1-Piperazino-3-Phenylindans and Related Compounds, Viborg, Denmark: Nørhaven (1998). pp. 1-144	<input type="checkbox"/>
	2	Klaus P. Bøgesø, "Neuroleptic Activity and Dopamine-Uptake Inhibition in 1-Piperazino-3-phenylindans," J. Med. Chem. 26(7): 935-47 (1983).	<input type="checkbox"/>
	3	Derek N. Eder, "CEE-03-310 CeNeS Pharmaceuticals," Curr. Op. Invest. Drugs. 3(2): 284-88 (2002).	<input type="checkbox"/>
	4	Mark J. Millan et al., "S18327 (1-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)]piperid-1-yl]ethyl)3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at $\alpha 2$ -Adrenergic Receptors: I. Receptorial, Neurochemical, and Electrophysiological Profile," J. Pharmacol. Exp. Ther. 292(1): 38-53 (2000).	<input type="checkbox"/>
	5	Vagn Pedersen and Klaus Bøgesø, "Drug Hunting," In Interviews by David Healy, The Psychopharmacologists II, pp. 561-79, London: Arnold (1999).	<input type="checkbox"/>
	6	Philip Seeman, Science & Medicine, "Dopamine Receptors and Psychosis," Sci. Amer. 28-37 (September/October 1995).	<input type="checkbox"/>
	7	Michael Bech Sommer et al., "Application of (2-Cyanoaryl)arylacetonitriles in Cyclization and Annulation Reactions. Preparation of 3-Arylindans, 4-Aryl-3,4-dihydronaphthalenes, 4-Arylisoquinolines, 1-Aminonaphthalenes, and Heterocyclic Analogues," J. Org. Chem. 55(16): 4822-27 (1990).	<input type="checkbox"/>
	8	Paul Willner, "Dopamine and Depression: A Review of Recent Evidence. I. Empirical Studies." Brain Res. Rev. 6: 211-24 (1983).	<input type="checkbox"/>
	9		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Emily Bernhardt/	Date Considered	05/10/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568572
Filing Date	2006-06-14
First Named Inventor	Heidi Lopez de Diego et al.
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	453-US-PCT

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568572
Filing Date	2006-08-14
First Named Inventor	Heidi Lopez de Diego et al.
Art Unit	1614
Examiner Name	N/A
Attorney Docket Number	453-US-PCT

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information disclosure statement. See 37 CFR 1.97(e)(2).

- ☒ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2007-08-01
Name/Print	Margaret M. Buck	Registration Number	54,010

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**